Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.

Cai TT, Li HQ, Jiang LL, Wang HY, Luo MH, Su XF, Ma JH

BioMed research international17 Sept 2021Cited by 64 (Europe PMC)

PMID34580638PMCIDPMC8464416DOI10.1155/2021/3361309PepBankPUB-34580638

Summary

IntroductionHypoglycemic drugs affect the bone quality and the risk of fractures in patients with type 2 diabetes mellitus (T2DM). We aimed to investigate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and insulin on bone mineral density (BMD) in T2DM.MethodsIn this single-blinded study, a total of 65 patients with T2DM were randomly assigned into four groups for 52 weeks: the exenatide group (n = 19), dulaglutide group (n = 19), insulin glargine group (n = 10), and placebo (n = 17). General clinical data were collected, and BMD was measured by dual-energy X-ray absorptiometry.ResultsCompared with baseline, the glycosylated hemoglobin (HbA1c) decreased significantly in the exenatide (8.11 ± 0.24% vs. 7.40 ± 0.16%, P = 0.007), dulaglutide (8.77 ± 0.37% vs. 7.06 ± 0.28%, P < 0.001), and insulin glargine (8.57 ± 0.24% vs. 7.23 ± 0.25%, P < 0.001) groups after treatment. In the exenatide group, the BMD of the total hip increased. In the dulaglutide group, only the BMD of the femoral neck decreased (P = 0.027), but the magnitude of decrease was less than that in the placebo group; the BMD of L1-L4, femoral neck, and total hip decreased significantly (P P P P = 0.001).ConclusionsCompared with the placebo, GLP-1RAs demonstrated an increase of BMD at multiple sites of the body after treatment, which may not exacerbate the consequences of bone fragility. Therefore, GLP-1RAs might be considered for patients with T2DM. This trial is registered with ClinicalTrials.gov NCT01648582.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, HbA1c decreased from 8.77% to 7.06% during dulaglutide treatment.
In plain wordsIn patients with diabetes, blood sugar measured by HbA1c decreased during dulaglutide treatment compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n = 19
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
HbA1c at baseline
8.77%
dulaglutide group, before treatment
HbA1c after treatment
7.06%
dulaglutide group, after 52 weeks
Source sentences
Summary
dulaglutide (8.77 ± 0.37% vs. 7.06 ± 0.28%, P < 0.001),
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-blinded study, a total of 65 patients with T2DM were randomly assigned into four groups for 52 weeks: the exenatide group (n = 19), dulaglutide group (n = 19), insulin glargine group (n = 10), and placebo (n = 17).
Show in the study text Report a problemFND-3458063801
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, femoral neck BMD fell in both the dulaglutide and placebo groups, with a smaller decrease in the dulaglutide group.
In plain wordsIn patients with diabetes, femoral neck bone density fell with both dulaglutide and placebo, and fell less with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFemoral neck BMD change
Study
n = 19
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
In the dulaglutide group, only the BMD of the femoral neck decreased (P = 0.027), but the magnitude of decrease was less than that in the placebo group;
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-blinded study, a total of 65 patients with T2DM were randomly assigned into four groups for 52 weeks: the exenatide group (n = 19), dulaglutide group (n = 19), insulin glargine group (n = 10), and placebo (n = 17).
Show in the study text Report a problemFND-3458063802
03HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, femoral neck BMD loss during dulaglutide treatment was smaller than with placebo.
In plain wordsPatients with diabetes lost less femoral neck bone density with dulaglutide than with placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFemoral neck BMD loss versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
In the dulaglutide group, only the BMD of the femoral neck decreased (P = 0.027), but the magnitude of decrease was less than that in the placebo group;
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-blinded study, a total of 65 patients with T2DM were randomly assigned into four groups for 52 weeks: the exenatide group (n = 19), dulaglutide group (n = 19), insulin glargine group (n = 10), and placebo (n = 17).
Show in the study text Report a problemFND-3458063803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01648582

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 774Jul 2012 to Dec 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 18 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.